슬롯게임 실시간 ┻ 카지노 슬롯머신 잭팟 ┻

알라딘먹튀 ┻ 현금게임 ┻▽ 91.rau798.top ※This article was released as Pharm Edaily Premium Content on July 22, 2025, at 10:00 AM.


[Shin-Min Joon, Edaily Reporter] On July 21 shares of Korean pharmaceutical and biotech companies saw notable movements. Protia posted a double digit gain, buoyed by expectations for the upcoming launch of a premium diagnostic kit capable of detecting 176 types of allergens in 가지급금인정이자계산 a single test.
SCL Science also advanced on optimism over improved performance at its subsidiary and enhanced shareholder value following a planned bonus issue.
In contrast HLB ex 최저 tended its decline for a second day after its U.S. subsidiary and Chinese partner Jiangsu Hengrui Pharma held a Type-A meeting with the U.S. FDA regarding their third attempt at securing approval for 집담보추가대출 rivoceranib (in combination with camrelizumab) for liver cancer.



Protia stock trend on July 21. (Image=MP Doctor)


Protia 직장인 개인사업자 Jumps on Imminent Launch of 176 Allergen Diagnostic Kit
Protia shares surged 13.04% to won 3,900, according to KG Zeroin and MP Doctor. The rally reflected expectations for the upcoming lau 골든브릿지증권 nch of its premium diagnostic kit, PROTIA Allergy-Q 192D, capable of testing for 176 allergens, including drugs and chemical antigens, in a single assay.
Protia plans to begin domestic sales in the second half of this year and expand exports to China and India. The company currently markets allergen panels testing up to 116 allergens, and it developed Korea’s first equine specific allergy diagnostic kit which tests for up to 120 allergens a marked improvement over the conventional 72 allergen panels.
The equine test significantly reduces costs and turnaround time compared to conventional skin prick tests or sending blood samples overseas, which could cost over won 1 million per test.
For the first half of 2025 Protia posted won 6.5 billion in revenue and won 1.5 billion in operating profit up 41.5% and 260.8% year on year respectively. Growth was driven by strong demand for human allergy diagnostics and a doubling of diagnostic equipment sales.
a company official said “We will drive both revenue and profit growth in the second half through new product launches and market expansion.”
SCL Science Gains on Subsidiary Investment and Bonus Issue
SCL Science rose 8.54% to won 3,115 fueled by expectations of improved financial performance at its subsidiary SCL Healthcare and a forthcoming 300% bonus issue.
SCL Healthcare recently secured a strategic investment from JNP Medi in the form of redeemable convertible preferred shares (RCPS) to be issued in two tranches by early next year. The funding will support the buildout of pharmacokinetics (PK) research infrastructure with plans to develop new healthcare services, AI-driven platforms, and advanced data analytics.
With PK capabilities expected to be operational by next year, SCL Healthcare aims to strengthen its position in the clinical research organization (CRO) market. The investment also paves the way for expanded partnerships and client acquisition.
SCL Science will issue 25.43 million new shares via a 300% bonus issue increasing total shares outstanding to 33.91 million. The record date was July 1 and the new shares are slated for listing on July 23.
The company is also advancing bio platform development through joint research with KAIST’s Translational Medicine Center, leveraging the SCL Group’s data assets and KAIST’s analytics expertise to develop disease risk prediction algorithms and discover new drug candidates.
an SCL Science official said “This bonus issue is aimed at rewarding shareholders and boosting liquidity, laying the groundwork for long-term value creation.” The company also pledged to pursue licensing deals AI powered new businesses and growth initiatives to enhance shareholder value.
HLB Falls Again Despite Positive FDA Type-A Meeting Update
HLB shares fell 4.91% to won 50,300 extending losses amid lingering uncertainties over FDA approval for its liver cancer drug Rivoceranib (with camrelizumab).
HLB and its U.S. unit Elevate Therapeutics are coordinating with Jiangsu Hengrui Pharma on the new drug application (NDA) process. On July 18, HLB announced that Jiangsu Hengrui had met with the FDA for a Type-A meeting to discuss responses to previous agency comments.
In an official blog post HLB stated the FDA “raised no objections” to the updated data but requested additional materials for submission. The company added that Jiangsu Hengrui would swiftly compile the requested data for the NDA resubmission.
HLB noted that the meeting details concern Jiangsu Hengrui’s manufacturing facilities, requiring coordination before public disclosure.
The classification of the NDA resubmission Class 1 (two-month review) or Class 2 (six-month review with potential reinspection) will determine the timeline.
While a Class 1 decision could expedite approval HLB cautioned that the FDA might still request further information keeping approval prospects uncertain.
Given this is the third NDA attempt HLB and Jiangsu Hengrui emphasized a cautious, thorough approach even if it delays resubmission beyond this year.
An HLB official said “We will meticulously prepare for a definitive approval based on close cooperation between Elevate Therapeutics and Jiangsu Hengrui.”
신민준 (adonis@edaily.co.kr)